Skip to main content
Biohit Oyj logo

Biohit Oyj — Investor Relations & Filings

Ticker · BIOBV ISIN · FI0009005482 LEI · 74370089ATTSNBXJVT29 HE Manufacturing
Open in API
Filings indexed 992 across all filing types
Latest filing 2019-01-31 Board/Management Inform…
Country FI Finland
Listing HE BIOBV

About Biohit Oyj

https://www.biohithealthcare.com/en/

Biohit Oyj is a global biotechnology company that develops, manufactures, and markets innovative diagnostic products and services. The company specializes in tools for the early diagnosis and prevention of diseases, with a primary focus on gastroenterology. Its key offerings include the GastroPanel® blood test for assessing stomach health and screening for risks of gastric cancer, as well as diagnostic tests for conditions such as Helicobacter pylori infection. Operating under the mission "Innovating for Health," Biohit's products are designed to support medical research, facilitate early and accurate diagnosis, and improve patient quality of life.

Recent filings

Filing Released Lang Actions
Business Development Director Lea Paloheimo will retire from Biohit Oyj
Board/Management Information Classification · 100% confidence The document explicitly announces that a 'Business Development Director' (a senior management role) 'will retire'. The content focuses entirely on this personnel change within the management team. This directly aligns with the definition of Board/Management Information (MANG), which covers 'Announcement of changes in the company's board of directors or senior management.' The document is short and is a direct announcement, not a placeholder for a larger report.
2019-01-31 English
Chief Medical Director Kari Syrjänen will retire from Biohit Oyj
Board/Management Information Classification · 100% confidence The document is a short announcement from Biohit Oyj regarding a change in senior management: the Medical Director, Kari Syrjänen, is retiring effective December 31, 2018. The title explicitly mentions 'Muutokset hallitus/johto/tilintarkastus' (Changes in board/management/audit), and the content confirms a management departure. This directly corresponds to the definition for Board/Management Information (MANG). The document length is very short (1356 chars), but it is the primary announcement itself, not an announcement *about* a report, so RPA/RNS is not the primary classification.
2018-12-31 Finnish
Chief Medical Director Kari Syrjänen will retire from Biohit Oyj
Board/Management Information Classification · 100% confidence The document explicitly announces a change in senior management: 'Chief Medical Director Kari Syrjänen will retire from Biohit Oyj'. This directly aligns with the definition of Board/Management Information, which covers announcements of changes in senior management. The filing type code for this is MANG.
2018-12-31 English
Biohit Oyj’s Financial Reporting and Annual General Meeting in 2019
Report Publication Announcement Classification · 99% confidence The document is a schedule outlining future corporate events for Biohit Oyj, specifically detailing the release dates for the 2018 Annual Report (Tilinpäätöstiedote), the Annual Report itself (Vuosikertomus), the date for the Annual General Meeting (varsinainen yhtiökokous), and the H1 2019 interim report. Since the document's primary function is to announce the timing of these future reports and meetings, and it explicitly mentions the AGM date and the publication of the Annual Report, it relates closely to investor relations and corporate scheduling. Given the options, the most fitting category for an announcement detailing the schedule of financial reports and the AGM is 'Report Publication Announcement' (RPA), as it announces *when* other reports will be published, or 'AGM Information' (AGM-R) due to the specific mention of the AGM date. However, since it covers the schedule for multiple reports (Annual, Interim) and the AGM, 'RPA' (Report Publication Announcement) is a strong fit for announcing the schedule itself. Alternatively, since it announces the date of the AGM, 'AGM-R' is plausible. Given the short length (2251 chars) and the nature of announcing future publication dates rather than containing the full content of the reports, RPA is the best fit for this scheduling notice.
2018-11-30 Finnish
Biohit Oyj’s Financial Reporting and Annual General Meeting in 2019
Report Publication Announcement Classification · 98% confidence The document is titled 'Biohit Oyj - Financial Calendar' and explicitly outlines the schedule for future financial reporting events, including the release of financial statements, the publication of the Annual Report, the date for the Annual General Meeting (AGM), and the half-year report date. Since this document is purely an announcement detailing *when* other reports and meetings will occur, rather than being the report itself (like 10-K or IR) or the AGM material (AGM-R), it fits best under the category for announcing the publication of reports. The document mentions the Annual General Meeting date, but it is not the AGM material itself, nor is it the voting results. It is a schedule announcement. Therefore, Report Publication Announcement (RPA) is the most appropriate classification, as it announces the publication dates of various reports.
2018-11-30 English
Biohit Oyj B-shares Subscribed with Stock Options I 2013
Share Issue/Capital Change Classification · 99% confidence The document is a press release from Biohit Oyj dated 5.11.2018, titled 'Biohit Oyj - Muutokset omien osakkeiden omistuksessa' (Changes in Own Shareholdings) and specifically details the subscription of new B-shares using option rights (I 2013). It reports the number of shares issued (52,709), the subscription price, the resulting total number of shares, and the registration date. This activity directly relates to the company managing its own share capital and transactions involving its own stock. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS), which covers share repurchase/issuance, or potentially 'Share Issue/Capital Change' (SHA). Since the transaction is explicitly about exercising options leading to the issuance of new shares, POS is the most precise fit for transactions involving the company's own stock pool, although SHA is also relevant. Given the context of option exercise resulting in new shares being issued, POS (Transaction in Own Shares) is the most specific classification for this type of capital movement.
2018-11-05 Finnish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.